Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention | Zendy

Robert W. Yeh | Zendy; Eric A. Secemsky | Zendy; Larry S. Dean | Zendy; SharonLise T. Normand | Zendy; Anthony Gershlick | Zendy; David J. Cohen | Zendy; John A. Spertus | Zendy; Philippe Gabríel Steg | Zendy; Donald E. Cutlip | Zendy; Michael J. Rinaldi | Zendy; Edoardo Camenzind | Zendy; William Wijns | Zendy; Patricia Apruzzese | Zendy; Yang Song | Zendy; Joseph M. Massaro | Zendy; Laura Mauri | Zendy

Open Access

Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention

Author(s) -

Robert W. Yeh,

Eric A. Secemsky,

Larry S. Dean,

SharonLise T. Normand,

Anthony Gershlick,

David J. Cohen,

John A. Spertus,

Philippe Gabríel Steg,

Donald E. Cutlip,

Michael J. Rinaldi,

Edoardo Camenzind,

William Wijns,

Patricia Apruzzese,

Yang Song,

Joseph M. Massaro,

Laura Mauri

Publication year - 2016

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2016.3775

Subject(s) - medicine , percutaneous coronary intervention , conventional pci , thienopyridine , aspirin , myocardial infarction , cardiology , randomized controlled trial , coronary artery disease , stent , cohort

Dual antiplatelet therapy after percutaneous coronary intervention (PCI) reduces ischemia but increases bleeding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research